Welcome to our dedicated page for Revive Therapeutics news (Ticker: RVVTF), a resource for investors and traders seeking the latest updates and insights on Revive Therapeutics stock.
Revive Therapeutics Ltd. develops specialty life sciences programs focused on infectious diseases and medical countermeasures. Company news commonly centers on Bucillamine, including intellectual-property filings, granted patent coverage, and research updates on its potential use in infectious diseases and nerve-agent exposure.
Revive updates also cover work with Defence R&D Canada – Suffield Research Centre, botanical research compounds, molecular hydrogen therapeutic programs, and financing activity. Capital-structure news includes private placements, debt settlement, unit issuances, common share purchase warrants, compensation options, and the use of proceeds for working capital and trade payables.
Revive Therapeutics (OTCQB:RVVTF) announced a proposed non-brokered private placement of up to 31,250,000 units at $0.032 per unit, for maximum gross proceeds of about $1,000,000.
Each unit includes one common share and a three‑year warrant exercisable at $0.05, with proceeds earmarked for working capital.
Revive Therapeutics (OTCQB:RVVTF) outlined a strategic expansion of its bucillamine program across infectious diseases, defence and biothreat medical countermeasures. Plans include new preclinical studies, pursuit of government and defence partnerships, and exploration of stockpiling and non-dilutive funding opportunities.
Revive highlighted a granted Canadian patent for infectious diseases (expiring March 16, 2041), North American patent filings for nerve-agent exposure, an ongoing collaboration with Defence R&D Canada, and bucillamine’s multi-decade clinical history as foundations for building a broader medical countermeasure platform.
Revive Therapeutics (OTCQB:RVVTF) announced North American patent filings for bucillamine in nerve agent exposure and a granted Canadian patent for infectious diseases. The Canadian patent (No. 3,172,170) was granted March 10, 2026 and expires March 16, 2041. U.S. and Canadian national phase filings under PCT/CA2024/000008 carry U.S. application 19/518,001 and Canadian application 3,304,264.
The moves expand Revive's IP in medical countermeasures and infectious diseases, support partnering/licensing potential, and align with an active research collaboration with Defence R&D Canada — Suffield Research Centre (DRDC).
Revive Therapeutics (OTCQB: RVVTF; CSE: RVV) provided an update on its collaborative research study with Defence R&D Canada – Suffield Research Centre (DRDC) evaluating Bucillamine as a potential treatment for nerve agent–induced brain injury. The company said the DRDC-led study is expected to conclude with results in January 2026. Any findings will be released only with the express authorization of DRDC. Revive indicated it will continue to provide updates as the study advances toward completion.
Revive Therapeutics (OTCQB: RVVTF) provided an update on an ongoing research study evaluating bucillamine as a potential treatment for nerve agent–induced brain injury.
The study is conducted in collaboration with Defence R&D Canada – Suffield Research Centre (DRDC), which is evaluating pharmacological compounds that may mitigate nerve agent effects. The study remains in progress and final findings will be released only with DRDC authorization. Revive said it will provide further updates as the study advances toward completion.
Revive Therapeutics (OTCQB: RVVTF), a specialty life sciences company, has completed the second tranche of its private placement by issuing 4,352,381 units at $0.021 per unit, raising gross proceeds of $91,400.
Each unit consists of one common share and one warrant, with warrants exercisable at $0.05 per share for 36 months. The proceeds will be used for working capital and trade payables settlement. Securities issued are subject to a four-month hold period ending January 19, 2026.
Revive Therapeutics (OTCQB: RVVTF) has announced an extension of its private placement offering. The company aims to raise up to $650,000 through the issuance of up to 30,952,381 units at $0.021 per unit. Each unit includes one common share and one warrant exercisable at $0.05 for 36 months.
The company has already completed a first tranche in August 2025, raising $60,900 through 2,900,000 units, leaving $589,000 worth of units available. The proceeds will be used for working capital and trade payables settlement. The securities will have a four-month and one-day hold period from issuance.
Revive Therapeutics (OTCQB: RVVTF) has completed the first tranche of its private placement offering, raising $60,900 through the issuance of 2.9 million units at $0.021 per unit. Additionally, the company settled $67,400 in debt through the issuance of 3.2 million units at the same price.
Each unit consists of one common share and one warrant exercisable at $0.05 for 36 months. The company also issued 100,000 compensation options to an investment dealer. The proceeds will be used for working capital and trade payables, with securities subject to a hold period until December 9, 2025.
Revive Therapeutics (OTCQB: RVVTF) has announced a proposed private placement offering of up to 30,952,381 units at $0.021 per unit, aiming to raise gross proceeds of up to $650,000. Additionally, the company plans to settle a $67,400 debt through the issuance of 3,209,523 units at the same price.
Each unit includes one common share and one warrant, with warrants exercisable at $0.05 per share for 36 months. The proceeds will be used for working capital and trade payables. The offering may close in multiple tranches, with securities subject to a four-month hold period.
Revive Therapeutics (OTCQB: RVVTF) has issued a clarification regarding its ongoing research study of Bucillamine as a potential nerve agent countermeasure. The study, conducted in partnership with Defence R&D Canada – Suffield Research Centre (DRDC), is investigating compounds that could mitigate nerve agent-induced brain injury.
The research is scheduled to continue through September 2025. Results will only be released with DRDC's explicit authorization. The company emphasized that any future research collaborations with DRDC would only be considered after the current study's completion and dependent on satisfactory results.